Immunocidin is being evaluated in the treatment of canine hemangiosarcoma by researchers at ISU College of Veterinary Medicine
NovaVive is a private Canadian immunobiology company founded in July, 2014. The Company acquired an advanced veterinary immunotherapeutic platform based on mycobacterium cell wall fraction (MCWF) technology with regulator-approved products for cattle, horses and dogs. These products are currently sold to veterinarians in the U.S.A., Canada, Australia and New Zealand. The Company's head office is located in Napanee, Ontario, Canada.
NovaVive's anticancer immunotherapeutic for dogs will be evaluated in a clinical study at Iowa State University (ISU) College of Veterinary Medicine in the treatment of splenic hemangiosarcoma (in combination with chemo).
learn more
It's World Antibiotic Awareness Week and NovaVive is doing its part to help address the concern about antibiotic resistance by offering antibiotic alternatives for animals to the veterinary community and livestock/pet owners.
learn more
The Company's regulator-approved immunotherapy for calf scours, Amplimune®, has received an Organic Materials Review Institute (OMRI) Listing in Canada. This means that Amplimune may be used in organic cattle production.
learn more
